Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

3.

Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.

Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A.

Endocrinology. 2005 Mar;146(3):1328-37. Epub 2004 Dec 2.

PMID:
15576463
6.

In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents.

Qiao LY, Zhande R, Jetton TL, Zhou G, Sun XJ.

J Biol Chem. 2002 Jul 19;277(29):26530-9. Epub 2002 May 2.

7.

Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes.

Gual P, Gonzalez T, Grémeaux T, Barres R, Le Marchand-Brustel Y, Tanti JF.

J Biol Chem. 2003 Jul 18;278(29):26550-7. Epub 2003 May 1.

8.

Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus.

Hartman ME, O'Connor JC, Godbout JP, Minor KD, Mazzocco VR, Freund GG.

J Biol Chem. 2004 Jul 2;279(27):28045-50. Epub 2004 Apr 27.

10.
11.

Renal activity of Akt kinase in obese Zucker rats.

Zdychová J, Kazdová L, Pelikanová T, Lindsley JN, Anderson S, Komers R.

Exp Biol Med (Maywood). 2008 Oct;233(10):1231-41. doi: 10.3181/0801-RM-29. Epub 2008 Jul 18.

PMID:
18641049
12.

Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.

Veilleux A, Houde VP, Bellmann K, Marette A.

Mol Endocrinol. 2010 Apr;24(4):766-78. doi: 10.1210/me.2009-0328. Epub 2010 Mar 4.

13.

Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells.

Andreozzi F, D'Alessandris C, Federici M, Laratta E, Del Guerra S, Del Prato S, Marchetti P, Lauro R, Perticone F, Sesti G.

Endocrinology. 2004 Jun;145(6):2845-57. Epub 2004 Mar 4.

PMID:
15001544
14.

Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner.

de Alvaro C, Teruel T, Hernandez R, Lorenzo M.

J Biol Chem. 2004 Apr 23;279(17):17070-8. Epub 2004 Feb 4.

15.

Insulin-induced stimulation of JNK and the PI 3-kinase/mTOR pathway leads to phosphorylation of serine 318 of IRS-1 in C2C12 myotubes.

Müssig K, Fiedler H, Staiger H, Weigert C, Lehmann R, Schleicher ED, Häring HU.

Biochem Biophys Res Commun. 2005 Sep 30;335(3):819-25.

PMID:
16099431
16.

IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells.

Ahmad F, Gao G, Wang LM, Landstrom TR, Degerman E, Pierce JH, Manganiello VC.

J Immunol. 1999 Apr 15;162(8):4864-75.

18.

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5. Epub 2001 Apr 3.

19.
20.

Supplemental Content

Support Center